The systemic amyloidosis therapeutic market consists of treatments targeting amyloid proteins that accumulate in tissues and organs. Amyloidosis occurs when normally soluble proteins abnormally fold into insoluble fibrils that deposit in tissues. There are different types of amyloid proteins that can accumulate including light chain (AL), wild-type transthyretin (ATTR-WT), and mutated transthyretin (ATTRm). Currently available treatments aim to reduce amyloid protein production and progression of organ damage. Key drugs include investigational antisense therapies, such as inotersen and patisiran for hereditary ATTR amyloidosis, as well as chemotherapy for AL amyloidosis.

The Global Systemic Amyloidosis Therapeutic Market is estimated to be valued at US$6.19 Billion in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024-2031.



Key Takeaways



Key players operating in the systemic amyloidosis therapeutic market are AstraZeneca, Attralus, Ionis Pharmaceuticals, Prothena Biosciences, and Alexion Pharmaceuticals. AstraZeneca's inotersen and Ionis Pharmaceutical's patisiran received FDA approval for hereditary ATTR amyloidosis in 2018 and 2019, respectively. Prothena Biosciences is also developing PRX004, an investigational antiserum therapy for AL amyloidosis.



The growing prevalence of systemic amyloidosis diseases is driving market demand. AL amyloidosis occurs in approximately 8,000 people annually in the United States. The prevalence of hereditary ATTR amyloidosis has been increasing with an aging population. Furthermore, growing awareness and accurate diagnosis of these rare diseases is expected to uncover additional patient populations.



The market is also expanding globally with increased access to novel amyloidosis treatments. Regional pharmaceutical companies are also developing competitive therapies for approval. For example, Japan's Mitsubishi Tanabe Pharma received approval for pragmatic in Japan as the first domestic drug for hereditary ATTR amyloidosis. Increased research funding and partnerships between pharmaceutical companies and amyloidosis foundations will also support further market growth.



Market drivers



A key driver is the increasing amyloidosis disease prevalence globally. As the average life expectancy rises worldwide, the pool of elderly patients susceptible to age-related amyloidosis like ATTR amyloidosis will continue growing significantly. Additionally, improved diagnostic capabilities are enabling more accurate identification of patients. This is expected to uncover additional prevalent patient numbers and drive the need for more effective amyloidosis treatments over the forecast period.



Impact of geopolitical situation on the growth of Systemic Amyloidosis Therapeutic Market



The current geopolitical instability across several regions is negatively impacting the growth of the global systemic amyloidosis therapeutic market. The ongoing Russia-Ukraine war has disrupted supply chains and manufacturing operations. Export restrictions imposed by countries have led to shortages of raw materials required for producing amyloidosis drugs. Additionally, allocation of healthcare budgets towards treating conflict-related injuries is diverting funds away from research on rare disease treatments. The market is also witnessing decreased sales of amyloidosis drugs in the territories affected by political conflicts and economic sanctions. Companies will need to establish alternative manufacturing hubs and strategize procurement of raw materials from new sources to mitigate supply disruptions. They also require exploring new distribution channels to gain entry in closed markets. While geopolitical issues remain a challenge for the near future, the market is expected to rebound once the situations become stable.



Geographical Regions with Concentrated Systemic Amyloidosis Therapeutic Market Value



North America leads the global systemic amyloidosis therapeutic market in terms of value, accounting for over 35% share. Presence of advanced healthcare infrastructure, high adoption of novel drugs, and sizeable patient population drive the large market size. Europe is another prominent regional market supported by favorable government initiatives for orphan disease research. Besides, the Asia Pacific market is gaining ground rapidly attributable to growing medical tourism, increasing healthcare spending, and expanding base of amyloidosis patients in highly populated nations like India and China. Japan also has a noticeable market share attributed to universal health insurance coverage and focus on rare disease treatments.



Fastest Growing Regional Market for Systemic Amyloidosis Therapeutics



The Asia Pacific market demonstrates high growth potential and emerges as the fastest growing regional market for systemic amyloidosis therapeutics. Improving access to healthcare through public and private insurance schemes, rising affluence, expanding healthcare infrastructure and increasing focus of international pharmaceutical companies on developing markets are some key factors fueling market growth. Government efforts to modernize pharmaceutical research and strengthen trade ties with Western countries attract greater investments towards amyloidosis drug development. China and India with their huge populations and gradual rise in elderly demographics present lucrative opportunities. Additionally, economic expansion in Southeast Asian nations is augmenting healthcare expenditures and driving the systemic amyloidosis therapeutic demand in the overall Asia Pacific region.

Get more insights on this topic : https://medium.com/@pragajitank24/systemic-amyloidosis-therapeutic-market-poised-for-rapid-growth-due-to-advancement-in-rna-4f3df2edee32

What Are The Key Data Covered In This Systemic Amyloidosis Therapeutic  Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Systemic Amyloidosis Therapeutic 's growth between 2024 and 2031.

:- Accurate calculation of the size of the Systemic Amyloidosis Therapeutic  and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Systemic Amyloidosis Therapeutic  Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Systemic Amyloidosis Therapeutic  vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:

1. Source: Coherent Market Insights, Public sources, Desk research

2. We have leveraged AI tools to mine information and compile it